Thrilled to release the first spatial, and the largest single cell study of Castleman Disease! We reveal the key role of stromal cells in all types of CD. 🧵 https://t.co/XjeRhQURfT @SanjayPatelMD @sanamloghavi @AaronGoodman33 @KMirza @MinaXu7 @weinberg_olga @hemepathguy

Good day to share my thesis paper in Tregs and FOXP3.

Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol—A prospective study @norwegian_protocol_for_ALL https://t.co/ikLG4HvZsk

Important mechanistic study on ICAHT from our French colleagues @GustaveRoussy highlighting that lymphodepletion alone is insufficient to explain prolonged cytopenia after CART …a second inflammation / CAR-mediated hit within the BM is needed 👆 https://t.co/Xtv7rcIUlX

Finally, we propose a unifying framework to define the concept of CAR T "persistence". We argue that the underlying mechanisms likely differ between active tumor killing vs. long-term immunosurveillance; we refer to this as "type I" and "type II" persistence, respectively. 5/

September’s academic rush is in full swing, but pausing here to celebrate my colleague Scott Rodig’s groundbreaking study: https://t.co/DALJ3puj35. This 3+ year prospective study of multiplexed immunofluorescence in a CLIA lab integrated into EMR (for over 2,000 patients!),

Publication alert! Pleased to share our new article on Idiopathic Multicentric Castleman Disease. Thank you everyone who contributed to this publication, and special gratitude to Bob Ohgami for your mentorship 😊 https://t.co/qP7wPfl5ve

https://t.co/X1LntqX2lQ

In a landmark scientific feat published in @NEJM, a @ChildrensPhila & @PennMedicine team treated the first patient with personalized #genetherapy, designed uniquely for newborn KJ, who was diagnosed with a rare #ureacycledisorder at birth. Learn more: https://t.co/aUS67Sncdy

2025 Atlantic Regional HematoPathology Meeting is taking place this week @NYUGSOM_Path in NYC! Don’t miss it! Organized by our own Chris Park, MD/PhD. @nyugrossman #pathology #hemepath #heme

Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms https://t.co/i5wKzJ13oP

#Pediatric Scientist Development Program grant was terminated. The federal grant that has sustained PSDP for over 35 years was abruptly ended with no opportunity for appeal. This is utterly unconscionable if you care about the health of children. https://t.co/XkMePPtG19

Proud to share our group latest paper in Nature. "Spatial immune scoring system predicts hepatocellular carcinoma recurrence." A game-changer for early-stage HCC management - high risk patients benefited from Immunotherapy - Dawn of Spatial Medicine? https://t.co/zxVGoekj7p Our

Gene therapy is transforming how we treat genetic disorders, but what if mutations in more than 30 genes can cause similar symptoms? Now published in @CellStemCell ( https://t.co/Ub72yvUo0c), we report the development of a universal gene therapy for Diamond Blackfan anemia. 1/n

Think you're doing science right? These 9 rules might shatter everything you believe about research...

Shortly after a patient received CAR T-cell therapy for relapsed CNS lymphoma, an aggressive CAR+ T-cell lymphoma was diagnosed. Subsequent analysis revealed the presence of an abnormal clone in an early apheresis specimen. Read the Brief Report: https://t.co/aGM4vO6Rg2

“Hunting down the elusive cytosolic-DNA sensor,” by Diane Mathis outlines how cGAS was discovered, and the crucial findings made by Zhijian “James” Chen, winner of the 2024 Basic Research #LaskerAward. https://t.co/hebaEEK7PK #Lasker2024 #LaskerLaureate #UTSWMed

📢 This Friday, we’re highlighting the largest spatial & single-cell characterization of Castleman Disease (CD) lymph node samples! 🎉 Congrats to @pillai_vinodh and lab. The study used a 44-plex PhenoCycler panel & single-cell tech to uncover novel cell types & pathways in CD.

Your body has over 200 lymph nodes, which can be thought of as a first line of defense against pathogens and even metastatic cancer spread. They are "decision structures" carefully composed of a slew of immune cell types acting in careful choreography when the body encounters

We establish that lymph node stromal cells are key players in the clinical and pathologic features of CD. But what causes stromal cell activation? Clonal stromal cells or some immune stimulus? And how can we stop the immune hyperactivation. Read the paper to find out!

They are PDGFR+ stromal cells that secrete IL-6. Purple indicates marked co-expression of IL-6 and PDGFR. IL6 is another key cytokine of CD that is responsible for fever, anemia, hypergammaglobulinemia and it all coming from lymph node stromal cells.